Advanced ALK/ROS1-positive NSCLC
1 clinical trials · Condition
◉ Watch Advanced ALK/ROS1-positive NSCLC
| Record | Firm | Date |
|---|---|---|
| Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib (NCT07633626) | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo | 2026-03-10 |
Track Advanced ALK/ROS1-positive NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.